LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a Healthcare company (Biotechnology) with a market capitalization of $110M. The Maz Rating grades it against the other companies in its sector.
LENZ Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.50, LENZ Therapeutics, Inc. trades at 8.7x sales and 0.6x book value. Over the last twelve months it generated about $13M of revenue and a net loss of $144M. It runs a gross margin of 80.2%, an operating margin of -1211.2% and a net margin of -1135.0%. It shows return on equity of -59.6%, return on invested capital of -77.8% and a free cash flow yield of -116.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.66. Over the past 52 weeks the share price ranged from $2.80 to $32.13, with a beta of 1.81.
LENZ Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 5 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.